121 related articles for article (PubMed ID: 9612066)
21. Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients.
Bonfanti P; Capetti A; Di Mattei P; Niero F; Rizzardini G
AIDS; 1998 Jun; 12(9):1111. PubMed ID: 9662213
[No Abstract] [Full Text] [Related]
22. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
23. [Approval of HIV protease inhibitors as the AIDS therapeutics of next generation].
Kiso Y
Nihon Rinsho; 1997 May; 55(5):1287-95. PubMed ID: 9155188
[TBL] [Abstract][Full Text] [Related]
24. Data in from first head-to-head protease inhibitor.
AIDS Patient Care STDS; 1998 Apr; 12(4):317. PubMed ID: 11361961
[No Abstract] [Full Text] [Related]
25. Ritonavir and indinavir one year later.
TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
[No Abstract] [Full Text] [Related]
26. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
Mascolini M
J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
[TBL] [Abstract][Full Text] [Related]
27. Influence of indinavir and ritonavir on warfarin anticoagulant activity.
Gatti G; Alessandrini A; Camera M; Di Biagio A; Bassetti M; Rizzo F
AIDS; 1998 May; 12(7):825-6. PubMed ID: 9619821
[No Abstract] [Full Text] [Related]
28. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
[TBL] [Abstract][Full Text] [Related]
29. Using ritonavir with indinavir in cases of virologic failure.
TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
[No Abstract] [Full Text] [Related]
30. Double protease inhibitor regimens with amprenavir show promise.
AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
[No Abstract] [Full Text] [Related]
31. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
Salmon-Céron D; Deleuze J; Coste J; Guerin C; Ginsburg C; Blanche P; Finkielsztejn L; Pecqueux L; Chaput S; Gorin I; Sicard D
Ann Med Interne (Paris); 2000 Jun; 151(4):297-302. PubMed ID: 10922958
[TBL] [Abstract][Full Text] [Related]
32. Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Tomasselli AG; Heinrikson RL
Biochim Biophys Acta; 2000 Mar; 1477(1-2):189-214. PubMed ID: 10708858
[TBL] [Abstract][Full Text] [Related]
33. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.
Markgren PO; Hämäläinen M; Danielson UH
Anal Biochem; 2000 Mar; 279(1):71-8. PubMed ID: 10683232
[TBL] [Abstract][Full Text] [Related]
34. AmFAR extols FDA on rapid approval of two protease inhibitors.
AIDS Patient Care STDS; 1996 Jun; 10(3):193-4. PubMed ID: 11361645
[No Abstract] [Full Text] [Related]
35. [FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92-3. PubMed ID: 15373070
[No Abstract] [Full Text] [Related]
36. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
37. HIV protease inhibitors.
Winslow DL; Otto MJ
AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
[No Abstract] [Full Text] [Related]
38. A review of low-dose ritonavir in protease inhibitor combination therapy.
Cooper CL; van Heeswijk RP; Gallicano K; Cameron DW
Clin Infect Dis; 2003 Jun; 36(12):1585-92. PubMed ID: 12802760
[TBL] [Abstract][Full Text] [Related]
39. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
Bowman MJ; Chmielewski J
Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
